We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
One More Step to Finalize Your Registration
An activation link has been sent to your email address.
Please check the email and activate your account now. It might take few minutes to get the email.
If you did not find it, please check your spam box.
Having problem receiving the email? Send again
Still cannot receive? Contact us
Email ：PharmaSources@imsinoexpo.com
Whatsapp ：+86-13621645194
Main Sales Markets: orth America,Central/South America,Western Europe,Eastern Europe,Australasia,Eastern Europe,Australasia,Asia,Middle East,Africa
Sample Provided: no
Therapeutic indications
Orlistat is for weight control, including weight loss, weight maintenance and prevention of weight regain in adults with an initial body mass index (BMI) of 30 or more.
Orlistat should be used in conjunction with a low fat, calorie-controlled diet.
Dose and method of administration
Adults
The recommended dose of Orlistat is one 120 mg capsule orally three times a day with each main meal (during or up to one hour after the meal). If a meal is missed, the dose of Orlistat may be omitted.
The patient should be on a nutritionally balanced, mildly hypocaloric diet that contains
approximately 30% of calories from fat. It is recommended that the diet should be rich in fruit and vegetables. The daily intake of fat, carbohydrate and protein should be distributed over three main meals.
Doses above 120 mg three times daily have not been shown to provide additional benefit.
The World Health Organisation (WHO) calculates Body Mass Index (BMI) using the following
equation:
BMI = weight (kg) /[height (m)]2
The WHO BMI classification for overweight adults is BMI ≥ 25, and for obese adults BMI ≥ 30.
Note, that these BMI values are age-independent and the same for both sexes. However, BMI may not correspond to the same degree of fatness across different populations due, in part, to different body proportions.
Paediatric population
The efficacy and safety of Xenical in children and adolescents below the age of 18 years have not been established
Follow all directions given to you by your doctor and pharmacist carefully
Audited Supplier
Pharma Sources Insight June 2024: Globalization on the Go
